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Abstract The catalytic (K) subunit of protein kinase CK2 and
the hematopoietic specific protein 1 (HS1) display opposite
effects on Ha-ras induced fibroblast transformation, by enhanc-
ing and counteracting it, respectively. Here we show the
occurrence of physical association between HS1 and CK2K as
judged from both far Western blot and plasmon resonance
(BIAcore) analysis. Association of HS1 with CK2K is drastically
reduced by the deletion of the HS1 C-terminal region (403^486)
containing an SH3 domain. HS1, but not its deletion mutant
HS1 v324^393, lacking a sequence similar to an acidic stretch of
the regulatory L-subunit of CK2, inhibits calmodulin phospho-
rylation by CK2K. These data indicate that HS1 physically
interacts with CK2K and down-regulates its activity by a
mechanism similar to the L-subunit.
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1. Introduction
Protein kinase CK2 (formerly termed ‘casein kinase-2’ or
‘-II’) is a ubiquitous, constitutively active Ser/Thr speci¢c pro-
tein kinase essential for cell viability, thought to play a role in
a wide spectrum of cellular function as judged from the huge
number and variety of its targets (s 160 known to date) many
of which are involved in signal transduction, gene expression,
protein synthesis and metabolic regulations (reviewed in Refs.
[1^4]). The regulation of CK2 is still enigmatic : its catalytic K-
subunit is spontaneously active in the absence of second mes-
sengers or phosphorylation events, by virtue of a unique in-
teraction between its N-terminal segment and the activation
loop which is kept in its open conformation [5,6]. Two cata-
lytic subunits (K and/or KP) are normally associated with two
regulatory L-subunits to form stable heterotetramers which do
not dissociate unless under denaturing conditions. The basal
activity of the holoenzyme is even higher than that of the
catalytic subunit toward many substrates, with a number of
notable exceptions however, exempli¢ed by calmodulin,
whose phosphorylation is actually inhibited by the L-subunit.
Based on these and other observations, it has been postulated
that the catalytic subunits of CK2 may also be present in the
cell as monomers, where they could play a role distinct from
that of the heterotetrameric holoenzyme [7^10]. Pertinent to
this may also be the ¢nding that misscheduled expression of
CK2 catalytic subunits cooperates with proto-oncogenes in
promoting tumors [11^13] and cell transformation [9]. Given
this scenario, the recent detection of proteins than can interact
with the individual CK2 subunits has opened the possibility
that the phosphorylating activity of this kinase may be regu-
lated in a novel way (reviewed in [10]). The growing list of
these ‘partners’ includes proteins that associate with either the
L or the catalytic subunits. Among the latter ones are HSP90
[14], nucleolin [15] and protein phosphatase 2A [11].
The recent report that the malignancy of Ha-ras trans-
formed ¢broblasts, which is enhanced by CK2K and KP [9],
is conversely suppressed by transfection with apoptosis in-
ducer hematopoietic speci¢c protein 1, HS1 [16] prompted
us to check if HS1 could also behave as a partner and a
regulator of CK2K. The results of this study are reported here.
2. Materials and methods
[Q-32P]ATP, chemiluminescence reagent (ECL) and secondary anti-
bodies were purchased from Amersham, protease inhibitor cocktail
from Boehringer Mannheim; all other chemicals were from Sigma.
Monoclonal anti-CK2K antibodies (1AD9) were kindly donated by
Dr. O.-G. Issinger (Odense University, Odense, Denmark), while
polyclonal anti-CK2L antiserum was prepared by immunization of a
rabbit with peptide 53^64 of human CK2L coupled to keyhole limpet
hemocyanin (KLH). Proline-rich peptide KGGRSRLPLPPLPPPG
and the CK2 substrate peptide RRRADDSDDDDD, were synthe-
sized with an automated peptide synthesizer ABI 431-A (Applied
Biosystem) equipped with Fmoc chemistry, according to a protocol
described elsewhere [17,18].
Full length (f.l.) HS1, HS1 v1^207 and HS1 v403^486 were ob-
tained and puri¢ed as previously described [19]. HS1 v324^393 was
obtained by cleavage of pTrcHis HS1 with DraIII and XhoI followed
by ligation of the oligonucleotides 5PGTGGAGGGGGAGTATG-
AGGTGC3P and 5PTCGAGGACCTCATAGTCCCCCTCCACTG-
G3P. Expression and puri¢cation were performed according to the
protocol described in [19].
CK2K wild-type (w.t.), CK2K mutant and CK2L were expressed in
E. coli as described in [20]. Puri¢cation of the isolated subunits was
obtained by phosphocellulose chromatography, as already described
[21]. CK2K K74^77A mutant was generated by an oligonucleotide
directed mutagenesis according to the method described in [22].
For the far Western experiments, HS1 or its mutants were blotted
to nitrocellulose membranes, which were then blocked with 3% (w/v)
bovine serum albumin and incubated with binding bu¡er (300 mM
KCl, 0.1% (v/v) Tween-20 and 20 mM Tris-HCl, pH 7.5) for 30 min at
4‡C. A solution of the interacting protein (CK2 K-subunit, L-subunit
or both) in the same bu¡er was then added at a ¢nal concentration of
30 Wg/ml for each protein and incubated at 4‡C for 2 h, with gentle
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stirring. After the unbound proteins had been removed by three wash-
ings with the same bu¡er, the membranes were incubated with the
appropriate antibodies followed by the appropriate biotinylated sec-
ond antibody. Detection was performed by alkaline phosphatase re-
action or alternatively with chemiluminescence. Quantitation and nor-
malization of the bands were obtained by analysis with an
ImageMaster VDS apparatus and software (Pharmacia Biotech).
For the surface plasmon resonance (SPR) analysis, a BIAcore X
system was used to analyze molecular interactions by means of the
SPR phenomenon [23]. CK2K was covalently linked to a Sensor Chip
CM5 (BIAcore) (carboxymethylated dextrane surface) using amine
coupling chemistry [24], as follows. On the surface, activated with
N-hydroxysuccinimide (NHS) and N-ethyl-NP-(3-dimethylaminopro-
pyl)-carbodiimide hydrochloride (EDC) according to the manufacter-
er’s instructions, a CK2K solution (18 Wg/ml) in 10 mM sodium ace-
tate, pH 5.5, was applied with a £ow rate of 5 Wl/min, at 25‡C.
Unreacted groups on the chip were then inactivated by 1 M ethanol-
amine-HCl, pH 8.5 and CK2K not covalently bound was removed
with 10 mM NaOH. A surface density of 5100 RU (resonance units)
was generated. HS1 solutions (500^2500 nM) were injected over the
surface with a £ow rate of 10 Wl/min in running bu¡er HBS (10 mM
HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v surfactant
P20) at 25‡C. After injections, HBS replaced the HS1 solutions in a
continuous £ow of 10 Wl/min; surface was regenerated by injection of
10 mM NaOH (20 Wl, £ow rate of 30 Wl/min). All samples were run
simultaneously over a £ow cell containing a blank surface (without
any immobilized protein); each sensorgram (time course of the SPR
signal) was subtracted of the response observed in this control £ow
cell and normalized to a baseline of 0 RU. The kinetic data were
interpreted according a simple 1:1 binding model and the rate con-
stants of the interactions were calculated using the SPR kinetic eval-
uation software BIAevaluation 3.0 (BIAcore). The reported values are
the means of 4 separate experiments, with S.E.M. values lower than
30%.
Phosphorylation of calmodulin (3 WM) was achieved by incubation
with 20 nM CK2K in the presence of 50 mM Tris-HCl, pH 7.5, 10 WM
[Q-32P]ATP, 12 mM MgCl2. Samples were analyzed by sodium dodec-
yl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed
by autoradiography and phosphorylation was quanti¢ed by analysis
with an InstantImager (Packard) apparatus. Peptide phosphorylation
assays were performed under the same conditions, using 0.1 mM
speci¢c peptide R3AD2SD5 as substrate; the degree of phosphoryl-
ation was evaluated by the method of phosphocellulose paper [25].
3. Results
The ¢nding that HS1 [26] and CK2K display opposite ef-
fects on the Ha-ras induced ¢broblast transformation [9,16]
prompted us to check the possibility that there might be phys-
ical and/or functional interactions between these two proteins,
possibly resulting in an attenuation of CK2K oncogenic po-
tential. Physical interactions between HS1 and CK2 were
clearly detectable by far Western blot experiments, in which
HS1 and its deletion mutants were resolved by SDS-PAGE
and transblotted, and the membranes were overlaid with
Fig. 1. Association of CK2K with HS1 in far Western experiments. Samples were run on SDS-PAGE and transblotted onto nitrocellulose mem-
branes, which were then overlaid by solutions (30 Wg/ml) containing the indicated proteins. Membranes were then probed with anti-CK2K
monoclonal antibodies. A: 0.1 Wg CK2K or 0.6 Wg HS1 as f.l. or deletion mutants were loaded as indicated. vN: HS1 truncated of region 1^
207; vC: HS1 truncated of region 403^486. B: 0.2 Wg CK2K and 0.2 Wg HS1 were loaded simultaneously on each lane. Where present in the
overlay step, the proline-rich peptide KGGRSRLPLPPLPPPG (Pro-peptide) was added at 1 mM concentration C: 0.1 Wg CK2K (lanes 1 and
4), 0.2 Wg (lanes 2 and 5) or 0.4 Wg (lanes 3 and 6) of HS1 were loaded. Where present in the overlay step, CK2L (30 Wg/ml) was in molar ex-
cess as compared to CK2K. D: 0.1 Wg CK2K (lanes 1 and 5), or increasing concentrations of HS1 (0.1 Wg in lanes 2 and 6; 0.2 Wg in lanes 3
and 7; 0.3 Wg in lanes 4 and 8) were loaded.
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solutions containing either CK2 subunits or CK2 holoenzyme.
Bound CK2 was then detected by using proper antibodies. As
shown in Fig. 1A a strong signal is detected when the K-sub-
unit of CK2 is used in the overlay step, while no association
was observed with the L-subunit (not shown). The N-terminal
truncation of HS1 did not prevent interaction, which con-
versely was nearly abolished by the C-terminal truncation
depriving HS1 of its Src homology 3 (SH3) domain. More-
over, the addition of a proline-rich peptide known to interact
with Src SH3 domain [27], along with CK2K during the over-
lay step, counteracted the association of K-subunit to HS1
(Fig. 1B). The interaction is not evident when the L-subunit
is added in a molar excess to the K-subunit during the overlay
step, indicating that the formation of the K2L2 tetramers pre-
vents the association of K with HS1 (Fig. 1C). It should be
noted that HS1 is also appreciably phosphorylated by CK2K,
in a manner which is counteracted by the L-subunit (unpub-
lished data). Interestingly, however, the CK2K mutant K74^
77A, which is severely defective in substrate recognition but
not in L-subunit binding [21], still interacts with HS1 as e⁄-
ciently as K w.t. (Fig. 1D), consistent with the concept that
physical interaction occurs through a mechanism which is
distinct from that of substrate recognition.
In the attempt to determine the kinetic parameters of the
HS1-CK2K interaction, a SPR approach was applied. CK2K
was immobilized on the sensor surface and HS1 was passed
over the sensor surface at a £ow rate of 10 ml/min. The
sensorgram, corroborating the concept that indeed HS1 inter-
acts with the K-subunit of CK2, is shown in Fig. 2. The dis-
sociation and association rate constants were calculated from
the curve as described in Section 2; they were found to be
4.46U1033 s31 and 2.24U104 M31 s31, respectively. The
equilibrium dissociation constant (KD) was 1.99U1037 M.
For sake of comparison, the values calculated with the L-sub-
unit (instead of HS1) were: Kdiss = 9.30U1034 s31,
Kass = 2.27U104 M31 s31, KD = 4.08U1038 M.
In order to see whether interaction with HS1 might a¡ect
CK2K catalytic activity, experiments were performed using
calmodulin as phosphorylatable substrate. Calmodulin was
chosen because it is a speci¢c substrate of the catalytic sub-
unit, una¡ected by CK2 holoenzyme, usable thereafter as an
indicator of free CK2K activity [9]. As shown in Fig. 3A, by
adding HS1 to CK2K an almost complete inhibition of cal-
modulin phosphorylation is observed. Such a dose dependent
inhibition of calmodulin phosphorylation is reminiscent of
that promoted by the addition of CK2 L-subunit (Fig. 3C),
in that both are promoted by concentrations that are nearly
Fig. 3. E¡ect of HS1 (A), HS1 v324^393 (B) or CK2L (C) on the
catalytic activity of CK2K. CK2K activity was tested by 10 min in-
cubation at 30‡C with 10 WM [Q-32P]ATP, 12 mM MgCl2 using ei-
ther 3 WM calmodulin (CaM) or 0.1 mM R3AD2SD5 peptide as
substrate, as indicated. Increasing concentrations of HS1, either w.t.
(A) or deleted (v324^393) (B), or CK2L (C), were added. CaM
phosphorylation was quanti¢ed by SDS-PAGE of the samples and
analysis with an InstantImager apparatus (Packard). Peptide phos-
phorylation was evaluated by the method of P-cellulose paper [25].
CK2K activity is expressed as percent of control, in the absence of
either HS1 or CK2L (1.2 pmol Pi and 20 pmol Pi with calmodulin
and peptide, respectively).Fig. 2. Detection of CK2K/HS1 association by SPR signal. The in-
teraction was measured with the SPR sensor system BIAcore X.
Shown are representative sensorgrams obtained by the injection of
35 Wl of HS1 at the indicated concentrations at a £ow rate of 10 Wl/
min over a sensor surface containing 5100 RU of immobilized
CK2K. The response obtained with a control sensor surface (with-
out CK2K) was subtracted to each sensorgram (see Section 2 for de-
tails). Resp. Di¡., response di¡erence; RU, resonance units.
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equimolar to that of CK2K and both are speci¢cally detect-
able only using calmodulin as substrate, whereas the phos-
phorylation of a peptide substrate is either una¡ected or
even stimulated by HS1 and L-subunit, respectively. The sim-
ilarity between down-regulation promoted by either HS1 or L-
subunit is further highlighted by the observation that a HS1
deletion mutant (v324^393), lacking a region similar to the
down regulatory domain of CK2 L-subunit (see Fig. 4), has
lost its inhibitory activity (Fig. 3B).
4. Discussion
The data presented here may provide a rationale to explain
the opposite e¡ects of CK2 K/KP and HS1 protein on Ha-ras
induced malignant transformation. Assuming that the onco-
genic potential of CK2 is due to imbalanced expression of its
catalytic subunits [9] which are in excess over the L-subunit,
resulting in the phosphorylation of a subset of substrates
which are otherwise una¡ected by the K2L2 holoenzyme, it
can be speculated that any partner of K, capable to surrogate
the negative function of L by binding to K and down-regulat-
ing its activity, will counteract its oncogenic potential. Here
we show that HS1 display both functions: it binds to CK2K,
as judged from both far Western blots and BIAcore analysis,
and, by doing that, it down-regulates kinase activity moni-
tored using calmodulin as substrate. The KD constant calcu-
lated from BIAcore analysis is consistent with high a⁄nity
binding of HS1 to CK2K. It should be recalled that associa-
tion with cellular partners is considered a crucial device by
which CK2 activity, which is not subjected to any kind of
tight control, can be subtly modulated [10]. While a pletora
of partners of the L-subunit have been detected, mostly
through the two-hybrid system approach [28] much fewer
are the known partners of the K-subunit, namely HSP90
[14], nucleolin [15] and protein phosphatase 2A [11]. The bind-
ing of HSP90 and nucleolin is counteracted by heparin, con-
sistent with the concept that they bind to the same site. How-
ever a CK2K mutant (K74^77A) which has lost the ability to
bind heparin [29] still interacts with HS1, consistent with a
mode of binding di¡erent from that of HSP90 and nucleolin.
E⁄cient binding of HS1 to CK2K is dependent on its C-
terminal region, including an SH3 domain, whose truncation
drastically reduces the ability to interact with CK2K. The
intervention of an SH3 domain is also supported by the e¡ect
of a proline-rich peptide known to interact with the Src SH3
domain, whose addition counteracts the association between
HS1 and CK2K (see Fig. 1B). This suggests that the SH3
domain of HS1 either directly interacts with CK2K, where a
proline-rich domain, including a P-X-X-P SH3 binding motif,
is present in its C-terminal region, or facilitates the binding
indirectly, by conferring to HS1 a conformation prone to
interaction. It should be noted in this respect that a proline-
rich domain potentially suitable for interacting with the SH3
domain is also present in HS1 itself. It seems that the latter
possibility is more likely, since the CK2KP subunit, where the
C-terminal proline-rich domain of the K-subunit is lacking,
still associates with HS1, albeit somewhat less strongly (un-
published).
Apparently, down-regulation of CK2K by HS1 and physical
association between the two proteins rely on di¡erent struc-
tural modules: e⁄cient down-regulation depends on a stretch
in the Pro/Glu-rich domain of HS1 which displays signi¢cant
homology to the N-terminal acidic segment of the L-subunit,
which is known to mediate the inhibitory e¡ect on catalytic
activity [30] (see Fig. 4). Its deletion, in fact, suppresses the
ability of HS1 to down-regulate CK2K, but not to associate
with it (not shown). It is expected, therefore, that CK2K
down-regulation by HS1 takes place through the same pseu-
do-substrate mechanism operating in the case of the L-sub-
unit.
In conclusion, our data are consistent with the view that
one of the modes HS1 displays its anti-proliferative functions
in hematopoietic cells is to ‘bu¡er’ CK2K/KP subunits in ex-
cess, (i.e. not combined with the L-subunit) and to neutralize
their activity toward speci¢c protein targets, whose phospho-
rylation may contribute to the onset of cell proliferation and
transformation. In vivo studies will be required to validate
this hypothesis, e.g. by assessing whether co-expression of
HS1 and of its mutants interferes with the observed coopera-
tive e¡ect of CK2K in inducing ¢broblast transformation [9].
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